A role for the immune system in advanced laryngeal cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 10 2020
27 10 2020
Historique:
received:
26
04
2020
accepted:
17
09
2020
entrez:
28
10
2020
pubmed:
29
10
2020
medline:
27
2
2021
Statut:
epublish
Résumé
To investigate the role of the altered activation of the immune system in the prognosis of patients affected by laryngeal squamous cell carcinoma (LSCC). We analyzed 56 patients with advanced LSCC divided into two groups according to their prognosis: the first group relapsed within 24 months after treatment, the second group had no evidence of disease at 2 years. The presence of stromal tumor infiltrating lymphocytes (TILs) at the tumor-host border was investigated. In 43 patients we evaluated the expression of 395 genes related to immune system activation through a next generation sequencing panel. Priority-LASSO models and clustering analyses were integrated with multivariate Cox proportional hazard modeling to identify independent genes associated with relapse and estimate hazard ratios in relation to gene expression and TILs. TILs and the expression of genes related with immune system activation (FCGR1A, IFNA17, FCRLA, NCR3, KREMEN1, CD14, CD3G, CD19, CD20 and CD79A) were significantly associated with prognostic factors or disease specific survival. In patients with lymph node metastases and advanced T stage (pT4), the expression of other genes was altered. Low TILs count was highly associated with relapse within 2 years (p < 0.001). Low TILs and altered expression of specific genes associated with tumor-immune systems interactions emerged as independent risk factors, associated to poor prognosis and relapse within 2 years in advanced LSCC. Evaluation of patients' immune profile could be useful for prognosis and future therapeutic approaches towards personalized therapy.
Identifiants
pubmed: 33110100
doi: 10.1038/s41598-020-73747-0
pii: 10.1038/s41598-020-73747-0
pmc: PMC7591515
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18327Commentaires et corrections
Type : ErratumIn
Références
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Annu Rev Immunol. 2007;25:525-60
pubmed: 17201682
BMC Cancer. 2018 Aug 13;18(1):816
pubmed: 30103707
Int Immunol. 2002 Sep;14(9):1075-83
pubmed: 12202404
Mol Cancer. 2019 Mar 30;18(1):63
pubmed: 30927923
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4120-5
pubmed: 12646700
Clin Exp Med. 2019 May;19(2):261-267
pubmed: 30877410
Life Sci. 2018 Aug 15;207:296-303
pubmed: 29920250
PLoS Comput Biol. 2017 Nov 3;13(11):e1005752
pubmed: 29099853
Oncotarget. 2016 Aug 2;7(31):49259-49267
pubmed: 27363032
Oncol Lett. 2018 Mar;15(3):3985-3990
pubmed: 29456743
J Clin Oncol. 2015 Oct 10;33(29):3305-13
pubmed: 26351341
Oncotarget. 2016 Oct 11;7(41):67166-67174
pubmed: 27564103
JAMA Otolaryngol Head Neck Surg. 2019 Nov 1;145(11):1012-1019
pubmed: 31486841
PLoS One. 2013 Jul 15;8(7):e69593
pubmed: 23869245
BMC Infect Dis. 2018 May 15;18(1):220
pubmed: 29764370
BMC Bioinformatics. 2018 Sep 12;19(1):322
pubmed: 30208855
Oncotarget. 2017 Aug 9;8(41):71002-71011
pubmed: 29050338
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
Immunotherapy. 2018 Sep;10(12):1041-1045
pubmed: 30185137
Acta Otorhinolaryngol Ital. 2019 Feb;39(1):2-8
pubmed: 30936573
Biomed Res Int. 2015;2015:347867
pubmed: 26161395
J Clin Oncol. 2015 Oct 10;33(29):3293-304
pubmed: 26351330
Blood. 2013 Feb 28;121(9):1563-73
pubmed: 23293080
PLoS One. 2012;7(6):e38711
pubmed: 22701698
J Clin Oncol. 2006 Aug 1;24(22):3693-704
pubmed: 16832122
Front Immunol. 2019 Feb 26;10:292
pubmed: 30863404
J Transl Med. 2012 Oct 03;10:205
pubmed: 23034130
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
J Laryngol Otol. 2016 Oct;130(10):948-953
pubmed: 27774922
Curr Top Microbiol Immunol. 2014;382:29-50
pubmed: 25116094
Front Immunol. 2019 Aug 27;10:2022
pubmed: 31507611
BMC Med. 2017 Jun 2;15(1):110
pubmed: 28571578
Int Immunopharmacol. 2020 Aug;85:106622
pubmed: 32485354
Cancer Lett. 2017 May 1;393:76-85
pubmed: 28223169
Cancer Res. 2003 Oct 1;63(19):6478-87
pubmed: 14559840
JAMA Otolaryngol Head Neck Surg. 2014 Sep;140(9):855-60
pubmed: 25144163
Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Jun;123(6):688-696
pubmed: 28411003
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
J Clin Oncol. 2016 Nov 10;34(32):3838-3845
pubmed: 27646946
Cancer Immunol Immunother. 2019 Feb;68(2):213-220
pubmed: 30361882
Head Neck. 2019 Nov;41(11):3906-3915
pubmed: 31433540
PLoS Pathog. 2015 Nov 03;11(11):e1005254
pubmed: 26529416
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Breast Cancer Res. 2011;13(6):R126
pubmed: 22151962
BMC Genomics. 2008 May 16;9:225
pubmed: 18485203
J Clin Oncol. 2018 Apr 10;36(11):1143-1169
pubmed: 29172863
Br J Radiol. 2001 Nov;74(887):983-6
pubmed: 11709461
Oncoimmunology. 2018 Aug 6;7(10):e1477461
pubmed: 30288343
Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20847-52
pubmed: 19934056
J Pathol. 2003 Jun;200(2):255-68
pubmed: 12754747
Clin Cancer Res. 2016 Sep 15;22(18):4746-55
pubmed: 27016308
Scientifica (Cairo). 2014;2014:970315
pubmed: 24741445
Eur J Immunol. 2002 Jan;32(1):87-96
pubmed: 11754007
Cytometry B Clin Cytom. 2018 Jul;94(4):683-687
pubmed: 29236355
Semin Oncol. 2002 Jun;29(3 Suppl 7):18-26
pubmed: 12068384
Sensors (Basel). 2009;9(1):386-403
pubmed: 22389607